Stressgen (VSE: SSB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Heat Shock who wrote (172)	6/14/2001 6:44:50 PM
From: Heat Shock	Read Replies (1) of 236

To all: a few conference call notes- CEO Korpolinski used the phrase "broadly-based HPV therapeutic" about HspE7. Positive feelings about the trials was general and much was rightly made of the action of HspE7 against multiple subtypes of the Human Papilloma Virus. One fact mentioned was that the 3 patients whose warts cleared completely had HPV sub-types 16 for one, 6, 11 and 16 for another and 16 and 54 for the last. A webcast of the guy presenting (see stressgen.com) was said to have other such data. They spoke of various data becoming available this year. Korpolinski mentioned "early 2002" as a possible time for an announcement concerning partnering strategy. The orphan drug indication, RRP, could be the "first filing"- recurrent respiratory papillomatosis. "One of the cardinal features of immunity is memory". HspE7 was prophylactic in animal studies. The obvious implication is that the possibility exists that HspE7 could have a preventative role as well as a curative one. Heat.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next